C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.

ABSTRACT:

Aim

The 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC) is approximately 11% and has only improved marginally over the last three decades. For operable PDAC, resection and adjuvant FOLFIRINOX chemotherapy is standard of care. There is growing interest in perioperative regimens to improve outcomes. The non-randomized Phase II study "Gemcitabine and Abraxane for resectable Pancreatic cancer" (GAP) demonstrated the feasibility of perioperative gemcitabine/abraxane. Long-term survival in PDAC requires an effective immune response; hence, we undertook this translational study of the GAP trial cohort to identify immune-oncology biomarkers for clinical use.

Methods

We combined Nanostring nCounter technology with immunohistochemistry to investigate the correlation be

SUBMITTER: Bonazzi VF 

PROVIDER: S-EPMC11733851 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature